Norwich Pharma Services Refines Business Strategy
Norwich, New York – December 16, 2014 – Norwich Pharma Services, a provider of contract manufacturing and clinical research services for the pharmaceutical industry, announced today that the company has refined its business strategy to focus on customers and partners with commercial phase programs.
“Norwich’s service offering centers around what we do best – commercial manufacturing of solid dosage products,” said John Bender, Norwich’s Vice President, Commercial Operations. “The Norwich team will support programs at registration or post approval stages. Our 375,000 square foot facility has available commercial capacity and can easily accommodate large-scale projects that require a wide variety of technology platforms.”
In addition to its manufacturing services, Norwich will continue to offer a full range of clinical research services including: pharmacokinetics studies in healthy volunteers; drug metabolism studies; dose proportionality studies; and multiple dose studies. Norwich also offers comprehensive, low-cost pharmacovigilance services for pre-marketing, product safety, post-marketing surveillance and data analysis.
About Norwich Pharma Services
Norwich is a contract manufacturing and clinical research services provider for solid oral pharmaceuticals. For more than 127 years, Norwich has provided its experience and an unparalleled regulatory compliance record to offer its customers greater flexibility, resources and speed for their commercial manufacturing projects. Visit www.norwichpharma.com for more information.
Media and Business Inquiries:
John Bender Vice President, Commercial Operations
Norwich Pharma Services
Tel: 630.898.4298
E-mail: john.bender@norwichpharma.com
Total Page Views: 1071
